Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript
10:15pm, Wednesday, 10'th Nov 2021
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates
07:05pm, Wednesday, 10'th Nov 2021
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st
Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
08:05am, Wednesday, 03'rd Nov 2021
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
04:49pm, Thursday, 28'th Oct 2021
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors
08:05am, Tuesday, 12'th Oct 2021
Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board Ms. Tregoning brings more than two decades of experience in biotechnology and public policy
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 01'st Oct 2021
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners
03:00pm, Thursday, 30'th Sep 2021
Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million. Spero will use the proceeds to prepare for t
Investment expected to extend Spero Therapeutics' cash runway into 2H 2023 Investment expected to extend Spero Therapeutics' cash runway into 2H 2023
Spero Therapeutics to Present Data at IDWeek 2021
08:05am, Thursday, 16'th Sep 2021
CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercial
Spero Therapeutics to Present at Three Upcoming Investor Conferences
08:05am, Tuesday, 07'th Sep 2021
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commerciali
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:25pm, Tuesday, 31'st Aug 2021
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)
01:43pm, Tuesday, 31'st Aug 2021
Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call Transcript
04:38pm, Saturday, 07'th Aug 2021
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call Transcript
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:33pm, Friday, 30'th Jul 2021
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
04:01pm, Wednesday, 07'th Jul 2021
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi
